Elevated expression of transmembrane tyrosine kinase receptor HER2 (Human Epidermal growth factor Receptor 2) on the surface of tumour cells characterises ~ 15–20% of breast cancer presentations and is associated with an invasive subtype and poor prognosis [1, 2]. Here, ERBB2 is linked to breast carcinoma.